J&J touts Rybrevant win in newly diagnosed lung cancer, with key Tagrisso head-to-head readout up next

An FDA accelerated approval in 2021 made Johnson & Johnson’s Rybrevant the first treatment for a specific subset of non-small cell lung cancer (NSCLC). Now, with a positive clinical trial readout, the company hopes to win a full approval and extend the drug to newly diagnosed patients.